

MUCOSAL VACCINE DELIVERY SYSTEMS: THE FUTURE OF IMMUNIZATION

— PART 1

Editors:

Shaweta Sharma

Aftab Alam

Akhil Sharma

Bentham Books

Mucosal Vaccine Delivery Systems: The Future of Immunization

(Part 1)

Edited by

Shaweta Sharma

*School of Medical and Allied Sciences
Galgotias University, Yamuna Expressway
Gautam Buddha Nagar, Uttar Pradesh-201310
India*

Aftab Alam

*School of Pharmacy Katihar Medical College
Campus Alkarim University Katihar-854106 Katihar
India*

&

Akhil Sharma

*R.J. College of Pharmacy, Raipur, Gharbara
Tappal, Khair Uttar Pradesh, India*

Mucosal Vaccine Delivery Systems: The Future of Immunization (*Part 1*)

Editors: Shaweta Sharma, Aftab Alam and Akhil Sharma

ISBN (Online): 978-981-5324-57-0

ISBN (Print): 978-981-5324-58-7

ISBN (Paperback): 978-981-5324-59-4

© 2025, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2025.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 MUCOSAL DELIVERY PLATFORMS: A COMPREHENSIVE OVERVIEW ...	1
<i>Sudhir Kumar, Shekhar Sharma, Rupali Sharma, Alok Bhardwaj and Koushal Dhamija</i>	
INTRODUCTION	2
CONVENTIONAL VS. NOVEL APPROACHES FOR MUCOSAL DELIVERY	3
TYPES OF MUCOSAL SURFACES	3
Oral Mucosa	4
Nasal Mucosa	5
Pulmonary Mucosa	5
Vaginal Mucosa	6
Rectal Mucosa	7
Ocular Mucosa	8
ADVANTAGES OF MUCOSAL DELIVERY	9
MECHANISMS OF MUCOSAL IMMUNITY	11
Innate Immune Responses at Mucosal Surfaces	11
Adaptive Immune Responses in Mucosal Tissues	12
Immunoglobulin Production and Mucosal Antibody Responses	13
CELLULAR RESPONSES IN MUCOSAL IMMUNITY	14
Involvement of Epithelial Cells in Mucosal Defense	14
Function of Dendritic Cells in Antigen Presentation	15
T cell Subsets and their Roles in Mucosal Immunity	16
Contribution of Innate Lymphoid Cells (ILCs) to Mucosal Defense	17
COMMON MUCOSAL DRUG DELIVERY PLATFORMS	18
APPLICATIONS OF MUCOSAL DELIVERY PLATFORMS	19
Vaccines	19
Peptide and Protein Therapeutics	20
Small Molecule Drugs	20
Gene Therapy	21
RECENT ADVANCES AND RESEARCH TRENDS	22
COMMERCIALIZATION AND MARKET TRENDS	24
CHALLENGES AND LIMITATIONS	25
FUTURE PERSPECTIVES	25
CONCLUSION	26
ACKNOWLEDGEMENTS	26
REFERENCES	26
CHAPTER 2 NASAL VACCINATION: BREAKING NEW GROUND IN IMMUNE RESPONSE	35
<i>Akhil Sharma, Shaweta Sharma, Akanksha Sharma, Anila Mishra and Pankaj Agrawal</i>	
INTRODUCTION	36
HISTORICAL CONTEXT	39
Evolution of Nasal Vaccination	39
Milestones in Nasal Vaccine Development	39
Early Successes and Challenges	40

NASAL IMMUNOLOGY	41
Anatomy of Nasal Mucosa	41
Immune Mechanisms in Nasal Cavity	42
Nasal-Associated Lymphoid Tissue (NALT)	42
ADVANTAGES OF NASAL VACCINATION	43
Direct Access to Mucosal Immune System	43
<i>Enhanced Immune Response</i>	43
<i>Local Protection</i>	44
<i>Needle-Free Administration</i>	44
<i>Improved Patient Compliance</i>	45
<i>Potential for Needlestick Injuries Reduction</i>	45
<i>Cost-Effective Delivery</i>	45
<i>Targeted Delivery to Mucosal Sites</i>	45
<i>Ease of Administration</i>	45
<i>Potential for Needle-Free Boosters</i>	45
<i>Stimulating Cross-Reactive Immunity</i>	46
TYPES OF NASAL VACCINES	46
Live Attenuated Vaccines	46
Inactivated Vaccines	47
Subunit Vaccines	47
DNA Vaccines	47
Recombinant Vector Vaccines	48
MECHANISMS OF IMMUNE RESPONSE	48
Antigen Uptake and Presentation	48
Mucosal Antibody Responses (IgA)	48
Activation of T Cells	49
Induction of Memory Responses	49
APPLICATIONS OF NASAL VACCINATION	50
Respiratory Infections	50
Enteric Infections	51
Sexually Transmitted Infections	52
Allergies and Autoimmune Diseases	53
<i>Allergies</i>	53
<i>Autoimmune Diseases</i>	54
CHALLENGES AND LIMITATIONS	54
Stability and Storage Issues	54
Mucosal Tolerance	56
Standardization of Nasal Vaccine Formulations	56
Regulatory Hurdles	56
FUTURE DIRECTIONS	56
CONCLUSION	57
ACKNOWLEDGEMENTS	58
REFERENCES	58

CHAPTER 3 ORAL VACCINES: A REVOLUTION IN PREVENTIVE MEDICINE 64

Shekhar Sharma, Rupali Sharma, Sudhir Kumar, Alok Bhardwaj and Koushal Dhamija

INTRODUCTION	65
ORAL VACCINES' ADVANTAGE OVER TRADITIONAL METHODS USED IN PREVENTION MEDICINE	67
TYPES OF ORAL VACCINES	69

Live Attenuated Vaccines	69
Inactivated Vaccines	70
Subunit Vaccines	71
Viral Vector Vaccines	73
DNA Vaccines	74
ADVANTAGES OF ORAL VACCINES	75
Ease of Administration	75
Improved Compliance	76
Cost-Effectiveness	76
Flexibility in Vaccine Design	77
Induction of Durable Immunity	77
Reduction of Needle-Related Injuries and Infections	77
Enhanced Mucosal Immunity	78
Broader Accessibility	78
ORAL VACCINE MECHANISM OF ACTION	79
Administration and Delivery	79
Antigen Uptake and Presentation	79
Antigen Processing and Presentation	80
Activation of T Cells	80
Stimulation of B Cells and Antibody Production	80
Induction of Systemic Immune Responses	80
Memory Cell Formation	80
DEVELOPMENT PROCESS	81
Vaccine Formulation	81
Preclinical Studies	81
Clinical Trials Phases	82
<i>Phase I: Safety</i>	82
<i>Phase II: Immunogenicity</i>	82
<i>Phase III: Efficacy</i>	82
Regulatory Approval Process	82
<i>Submission of Regulatory Applications</i>	83
<i>Review and Evaluation</i>	83
<i>Advisory Committee Review</i>	83
<i>Regulatory Decision</i>	83
MARKETED PREPARATIONS OF VACCINES	83
Oral Polio Vaccine (OPV)	83
<i>Types of Oral Polio Vaccine (OPV)</i>	84
<i>Mechanism of Action of Oral Polio Vaccine (OPV)</i>	85
Rotavirus Vaccine	85
<i>Types of Rotavirus Vaccines</i>	85
Cholera Vaccine	87
<i>Types of Cholera Vaccines</i>	87
<i>Vaccination Strategies:</i>	88
Typhoid Vaccine	89
<i>Types of Typhoid Vaccines</i>	89
INNOVATIVE APPROACHES IN ORAL VACCINES	91
Mucosal Immunization	91
Targeted Antigen Delivery Systems	91
Adjuvant Formulation	92
Genetically Engineered Attenuated Strains	92
Virus-Like Particle Vaccines	92

Edible Plant-Based Vaccines	92
Synthetic Biology Approaches	92
CHALLENGES AND LIMITATIONS	93
FUTURE PERSPECTIVES	94
CONCLUSION	95
ACKNOWLEDGEMENTS	95
REFERENCES	95
 CHAPTER 4 PULMONARY VACCINATION: INHALABLE SOLUTIONS FOR	
RESPIRATORY DISEASES	106
<i>Akhil Sharma, Shaweta Sharma, Mobeen Shaik, Hrithik Dey and Pankaj Agrawal</i>	
INTRODUCTION	107
Challenges of Traditional Vaccination Methods	108
TYPES OF RESPIRATORY DISEASES	110
Influenza (Flu)	111
COVID-19	111
Pneumonia	112
Chronic Obstructive Pulmonary Disease (COPD)	112
Asthma	113
Tuberculosis (TB)	113
Respiratory Syncytial Virus (RSV) Infection	114
Interstitial Lung Diseases (ILDs)	115
Lung Cancer	115
Obstructive Sleep Apnea (OSA)	116
Cystic Fibrosis	117
Pulmonary Embolism	118
Bronchiectasis	119
IMPACT OF RESPIRATORY DISEASES ON GLOBAL HEALTH AND ECONOMY	120
THE PROMISE OF INHALABLE VACCINES	121
Advantages of Inhalable Vaccines Over Traditional Routes	122
<i>Needle-free Administration</i>	122
<i>Targeted Delivery to Respiratory Tract</i>	123
<i>Enhanced Mucosal Immunity</i>	123
<i>Ease of Administration and Mass Vaccination</i>	123
<i>Improved Vaccine Stability and Storage</i>	123
<i>Potential for Needle-free Boosters</i>	123
Mechanisms of Action for Inhalable Vaccines	124
DEVELOPMENT AND DELIVERY SYSTEMS	125
Various Forms of Inhalable Vaccines	125
<i>Dry Powder Formulations</i>	125
<i>Liquid Aerosols</i>	125
<i>Liposomal Formulations</i>	125
<i>Nanoparticle Formulations</i>	126
Challenges in Designing Effective Delivery Systems	126
<i>Particle Size and Distribution</i>	126
<i>Stability of Vaccine Antigens</i>	126
<i>Inhaler Device Performance</i>	127
<i>Pulmonary Tolerance and Safety</i>	127
<i>Immunogenicity and Efficacy</i>	127
<i>Regulatory Requirements and Approval</i>	127
APPLICATIONS IN RESPIRATORY DISEASE CONTROL	128

Prevention of Respiratory Infections	128
Management of Chronic Respiratory Diseases	128
Immunization in Special Populations	128
Rapid Response to Respiratory Outbreaks	128
Targeted Vaccination Strategies	129
SAFETY AND REGULATORY CONSIDERATIONS	129
Safety Concerns Associated with Inhalable Vaccines	129
Regulatory Pathways for Approval and Distribution	130
FUTURE PERSPECTIVES	130
CONCLUSION	131
ACKNOWLEDGEMENTS	132
REFERENCES	132
CHAPTER 5 MUCOSAL VACCINES FOR GASTROINTESTINAL INFECTIONS	139
<i>Neeraj Kumar Fuloria, Akhil Sharma, Sunita, Akanksha Sharma and Shaweta Sharma</i>	
INTRODUCTION	140
Prevalence and Impact of Gastrointestinal Infections	141
Mucosal Vaccines and their Relevance	142
TYPES OF GASTROINTESTINAL INFECTIONS	143
Bacterial Infections	143
<i>Salmonella</i> spp.	144
<i>Escherichia coli</i> (<i>E. coli</i>)	145
<i>Campylobacter</i> spp.	145
<i>Shigella</i> spp.	146
<i>Vibrio</i> spp.	147
<i>Clostridium difficile</i>	147
Viral Infections	148
<i>Norovirus</i>	148
<i>Rotavirus</i>	149
<i>Adenovirus</i>	150
<i>Enteric Adenoviruses</i>	151
Parasitic Infections	151
<i>Giardia lamblia</i>	151
<i>Cryptosporidium</i> spp.	152
<i>Entamoeba Histolytica</i>	153
<i>Cyclospora cayetanensis</i>	154
<i>Toxoplasma gondii</i>	154
Fungal Infections	155
<i>Candida albicans</i>	155
<i>Cryptococcus neoformans</i>	156
CHALLENGES IN GASTROINTESTINAL INFECTION CONTROL	157
Transmission Routes and Risk Factors	157
Antibiotic Resistance in Bacterial Infections	157
Lack of Effective Treatments for Viral and Parasitic Infections	158
ROLE OF VACCINES IN GASTROINTESTINAL INFECTION PREVENTION	158
Preventing Viral Infections	158
Reducing Transmission	159
Preventing Complications	159
Improving Public Health Outcomes	159
MUCOSAL IMMUNE SYSTEM IN THE GASTROINTESTINAL TRACT	160

Anatomy of the Gastrointestinal Mucosa	160
<i>Epithelial Layer</i>	160
<i>Lamina Propria</i>	161
<i>Muscularis Mucosae</i>	161
<i>Submucosa</i>	161
<i>Blood and Lymphatic Vessels</i>	161
<i>Enteric Nervous System (ENS)</i>	161
Mucosa-Associated Lymphoid Tissue (MALT)	162
<i>Antigen Sampling and Presentation</i>	162
Induction of Immune Responses	162
Secretory IgA Production	162
Tolerance Induction	162
Secretory IgA Antibodies and their Role in Defence	163
<i>Barrier Function</i>	163
<i>Neutralization of Pathogens</i>	163
<i>Agglutination and Immobilization</i>	163
<i>Transport across Mucosal Epithelium</i>	163
<i>Promotion of Commensal Tolerance</i>	164
CHALLENGES AND FUTURE PERSPECTIVES	164
CONCLUSION	165
ACKNOWLEDGEMENTS	165
REFERENCES	166

CHAPTER 6 UROGENITAL VACCINATION: ADDRESSING STIS AND BEYOND 173

Amana Parveen, Shekhar Singh, Dimple Singh Tomar, Akhil Sharma and Shaweta Sharma

INTRODUCTION	174
Targeted Protection	174
Reducing Transmission Rates	175
Preventing Complications	176
Long-Term Immunity	176
Simplifying Prevention Efforts	177
Addressing Urogenital Health Holistically	178
CURRENT LANDSCAPE OF STIS	178
Statistics on the Prevalence of STIs Globally.	178
Impact of STIs on Public Health and Individual Well-Being	179
CHALLENGES IN STI PREVENTION	180
Factors Contributing to the Spread of STIs	180
<i>Unprotected Sexual Behaviors</i>	180
<i>Lack of Comprehensive Sex Education</i>	180
<i>Stigma and Discrimination</i>	180
<i>Limited Access to Healthcare Services</i>	181
<i>Drug and Alcohol Use</i>	181
<i>Gender and Power Dynamics</i>	181
<i>Social Determinants of Health</i>	181
<i>Globalization and Travel</i>	181
Limitations of Current Prevention Strategies	182
<i>Inconsistent or Incorrect Usage</i>	182
<i>Condom Failure Rates</i>	182
<i>Limited Protection against Some STIs</i>	183
Behavioral Interventions Depend on Individual Adherence	183

Stigma and Cultural Barriers	184
Limited Access to Prevention Services	184
Efficacy Varies across Populations	185
Failure to Address Root Causes	186
UROGENITAL VACCINATION: AN INNOVATIVE APPROACH	186
COMMON PATHOGENS CAUSING STIS	188
Chlamydia trachomatis	188
Neisseria gonorrhoeae	189
Treponema pallidum	190
Human papillomavirus (HPV)	190
Herpes simplex virus (HSV)	191
HIV (Human Immunodeficiency Virus)	191
RESEARCH AND DEVELOPMENT	192
Overview of Ongoing Research into Urogenital Vaccines	192
<i>Vaccine Development</i>	192
<i>Efficacy Studies</i>	193
<i>Adjuvant and Delivery Systems</i>	193
<i>Broad-spectrum Protection</i>	193
<i>Immunological Mechanisms</i>	193
<i>Integration with Other Prevention Strategies</i>	193
Challenges Faced in Developing Effective Vaccines for Urogenital Pathogens	194
<i>Antigenic Variation</i>	194
<i>Mucosal Immunity</i>	194
<i>Host-Pathogen Interactions</i>	194
<i>Lack of Correlates of Protection</i>	194
<i>Safety Concerns</i>	194
<i>Delivery Systems and Adjuvants</i>	195
<i>Public Perception and Stigma</i>	195
ETHICAL CONSIDERATIONS	195
Vaccine Safety and Efficacy	195
Equitable Access	196
FUTURE IMPLICATIONS	197
CONCLUSION	198
ACKNOWLEDGEMENTS	198
REFERENCES	198
CHAPTER 7 MUCOSAL VACCINATION IN PEDIATRIC MEDICINE	206
<i>Ashish Srivastava, Shekhar Singh, Dimple Singh Tomar, Shaweta Sharma and Akhil Sharma</i>	
INTRODUCTION	207
Importance in Pediatric Medicine	208
MUCOSAL IMMUNE SYSTEM	209
Role in Immune Response	210
Differences from Systemic Immunity	212
ADVANTAGES OF MUCOSAL VACCINATION	213
Site-Specific Immunity	213
Needle-Free Administration	214
Enhanced Mucosal Immune Responses	215
Improved Vaccine Stability	216
Cross-Protection	216
Reduced Systemic Side Effects	217

Potential for Needle-Free Booster Doses	218
MUCOSAL VACCINES	218
Types of Mucosal Vaccines	219
<i>Oral Vaccines</i>	220
<i>Nasal Vaccines</i>	221
<i>Sublingual Vaccines</i>	222
CHALLENGES AND CONSIDERATIONS	223
Stability and Delivery Issues	223
<i>Stability</i>	223
<i>Delivery</i>	224
Immune Tolerance	224
Regulatory Hurdles	225
APPLICATIONS IN PEDIATRIC MEDICINE	226
Prevention of Gastrointestinal Infections	226
<i>Promotion of Breastfeeding</i>	226
<i>Safe Water and Sanitation</i>	227
<i>Hand Hygiene</i>	227
<i>Safe Food Handling</i>	227
<i>Vaccination</i>	227
<i>Hygienic Environment</i>	227
Protection Against Respiratory Pathogens	228
<i>Vaccination</i>	228
<i>Exclusive Breastfeeding</i>	228
<i>Hand Hygiene and Respiratory Etiquette</i>	228
<i>Environmental Hygiene</i>	228
<i>Avoiding Exposure to Tobacco Smoke and Air Pollution</i>	229
<i>Early Detection and Treatment</i>	229
Strategies for Vaccine Development Tailored to Children	229
<i>Formulation Optimization</i>	229
<i>Age-Appropriate Immunization Schedules</i>	229
<i>Safety Testing in Pediatric Populations</i>	229
<i>Immunogenicity Studies</i>	230
<i>Adaptive Trial Design</i>	230
<i>Post-Marketing Surveillance</i>	230
<i>Community Engagement and Education</i>	230
<i>Global Access and Equity</i>	230
CLINICAL TRIALS AND RESEARCH	230
PUBLIC HEALTH IMPLICATIONS	231
Role in Global Vaccination Strategies	231
Potential for Disease Eradication	231
CONCLUSION	232
ACKNOWLEDGEMENTS	233
REFERENCES	233
CHAPTER 8 IMMUNOSENESCENCE AND MUCOSAL VACCINATION IN THE ELDERLY	
PATIENTS	241
<i>Parul Srivastava, Shekhar Singh, Dimple Singh Tomar, Shaweta Sharma and Akhil Sharma</i>	
INTRODUCTION	242
UNDERSTANDING IMMUNOSENESCENCE	243
Age-Related Changes in the Immune System	243

Decline in Immune Function and Adaptive Responses	245
Impact of Immunosenescence on Vaccine Efficacy and Susceptibility to Infections	246
KEY FEATURES OF IMMUNOSENESCENCE	247
Decreased Immune Response	248
Thymic Involution	248
Reduced T Cell Function	249
Impaired B Cell Function	249
Increased Inflammation	250
Dysregulation of Cytokines	251
Altered Immune Cell Communication	251
EFFECTS ON VACCINE RESPONSE	252
Decreased Vaccine Efficacy	252
Impaired Mucosal Immunity	254
Reduced Secretory IgA Levels	254
Altered Immune Cell Composition	255
Delayed or Diminished Immune Memory	255
Increased Susceptibility to Respiratory Infections	256
MUCOSAL VACCINATION AS A POTENTIAL SOLUTION	256
Advantages of Mucosal Vaccination in Overcoming Immunosenescence-Related Barriers	256
<i>Localized Immune Response</i>	257
<i>Enhanced IgA Production</i>	257
<i>Needle-Free Administration</i>	258
<i>Induction of Cross-Reactive Immunity</i>	258
<i>Potential for Needle-Free Boosters</i>	259
Mechanisms of Mucosal Vaccines in Eliciting Immune Responses	260
<i>Antigen Uptake and Presentation</i>	260
<i>Induction of Secretory IgA Antibodies</i>	260
<i>Activation of MALT</i>	260
<i>Recruitment of Effector Cells</i>	261
<i>Induction of Mucosal Memory Responses</i>	261
<i>Stimulation of Innate Immune Responses</i>	261
EFFICACY OF MUCOSAL VACCINATION IN THE ELDERLY	261
Evidence from Studies on Mucosal Vaccine Efficacy in Elderly Populations	261
<i>Influenza Vaccines</i>	261
<i>Pneumococcal Vaccines</i>	262
<i>Herpes Zoster Vaccines</i>	262
Comparative Effectiveness with Traditional Parenteral Vaccines	262
CHALLENGES AND CONSIDERATIONS	263
FUTURE DIRECTIONS AND RESEARCH OPPORTUNITIES	264
CONCLUSION	265
ACKNOWLEDGEMENTS	266
REFERENCES	266
SUBJECT INDEX	273

FOREWORD

The field of immunization is undergoing a transformative shift with the advent of mucosal vaccine delivery systems. *Mucosal Vaccine Delivery Systems: The Future of Immunization – Part I* provides a comprehensive exploration of the latest advancements in this field, highlighting its potential to revolutionize disease prevention. This volume delves into various mucosal delivery platforms, offering insights into nasal, oral, pulmonary, gastrointestinal, and urogenital vaccinations. Special emphasis is placed on their role in pediatric immunization and addressing immunosenescence in elderly patients. By targeting mucosal surfaces, the body's first line of defense these innovative approaches enhance immune response and improve patient compliance. As global health challenges evolve, mucosal vaccines promise to bridge existing gaps in disease prevention. This book serves as a crucial resource for researchers, clinicians, and healthcare professionals dedicated to advancing immunization strategies for a healthier future.

Shivkanya Fuloria

Pharmaceutical Chemistry Unit
Faculty of Pharmacy, AIMST University
Kedah 08100 Malaysia

PREFACE

Mucosal vaccine delivery systems have emerged as a groundbreaking approach in immunization, offering a non-invasive and effective alternative to traditional methods. By targeting mucosal surfaces, the primary entry points for many pathogens these vaccines harness the body's natural immune defenses to provide enhanced protection. This book, *Mucosal Vaccine Delivery Systems: The Future of Immunization – Part I*, explores the latest advancements, challenges, and opportunities in this rapidly evolving field.

The book covers various mucosal delivery platforms, including nasal, oral, pulmonary, and urogenital vaccines. Nasal vaccination enhances both local and systemic immunity, while oral vaccines provide a needle-free, patient-friendly alternative. Pulmonary vaccines offer inhalable solutions for respiratory diseases, and urogenital vaccination addresses sexually transmitted infections. Additionally, mucosal vaccines for gastrointestinal infections are explored, highlighting their role in combating enteric pathogens.

Special focus is given to pediatric and elderly populations. Mucosal vaccines reduce distress in children while ensuring effective immune responses. In elderly patients, they help counter immunosenescence, enhancing vaccine efficacy. As global health challenges persist, mucosal vaccination represents the future of immunization. We hope this book serves as a valuable resource, inspiring innovation and collaboration toward more accessible and efficient vaccines worldwide.

Shaweta Sharma

School of Medical and Allied Sciences
Galgotias University, Yamuna Expressway
Gautam Buddha Nagar, Uttar Pradesh-201310
India

Aftab Alam

School of Pharmacy Katihar Medical College
Campus Alkarim University Katihar-854106 Katihar
India

&

Akhil Sharma

R.J. College of Pharmacy, Raipur, Gharbara
Tappal, Khair Uttar Pradesh, India

List of Contributors

Alok Bhardwaj	Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India
Akhil Sharma	R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India
Akanksha Sharma	R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India
Anila Mishra	Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, Near Malhaur Rly Station, P.O. Chinhath, Lucknow, U. P., 226028, India
Amana Parveen	PSIT-Pranveer Singh Institute of Technology Pharmacy, Jargaon, India
Ashish Srivastava	PSIT -Pranveer Singh Institute of Technology Pharmacy, Jargaon, India
Dimple Singh Tomar	Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, India
Hrithik Dey	Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India
Koushal Dhamija	Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India
Mobeen Shaik	KL College of Pharmacy, Koneru Lakshmaiah Education Foundation (Deemed to be University), Andhra Pradesh, India
Neeraj Kumar Fuloria	Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling Campus, Jalan Bedong-Semeling, Bedong, Kedah Darul Aman, Malaysia
Pankaj Agrawal	Guru Gobind Singh Indraprastha University, Govt of NCT of Delhi, Sector 16C, Dwarka, New Delhi, 110078, India
Parul Srivastava	PSIT -Pranveer Singh Institute of Technology Pharmacy, Jargaon, India
Rupali Sharma	Amity University Haryana, Manesar, Gurugram, India
Sudhir Kumar	Faculty of Pharmaceutical Sciences, DAV University, Jalandhar, Punjab, India
Shaweta Sharma	School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India
Shekhar Sharma	Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India
Sunita	Metro College of Health Sciences and Research, Greater Noida, India
Shekhar Singh	Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India

CHAPTER 1

Mucosal Delivery Platforms: A Comprehensive Overview

Sudhir Kumar^{1,*}, Shekhar Sharma², Rupali Sharma³, Alok Bhardwaj² and Koushal Dhamija²

¹ Faculty of Pharmaceutical Sciences, DAV University, Jalandhar, Punjab, India

² Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India

³ Amity University Haryana, Manesar, Gurugram, India

Abstract: Drug administration using mucosal delivery platforms holds great promise because of several advantages, including quick response, bypassing first-pass metabolism, and increased patient adherence. However, the effective exploitation and shaping of these avenues depend on deep knowledge of immunology principles at the mucosa. The oral, nasal, pulmonary, vaginal, rectal, and ocular mucosae are equipped with intricate defense systems executed by innate as well as adaptive immunity. This chapter explores the intersection of mucosal delivery platforms and mucosal immunity. Beginning with an introduction to mucosal delivery and its importance in drug delivery, we delve into the challenges of mucosal barriers, clearance mechanisms, and immunogenicity. It is very important to comprehend how mucosal immunity works, which includes the function of epithelial cells, dendritic cells, T cells, and innate lymphoid cells in defending the body. Furthermore, we examine common mucosal delivery platforms such as lipid-based formulations, nanoparticles, hydrogels, and microneedle patches, highlighting their applications in vaccine delivery, protein therapeutics, small molecule drugs, and gene therapy. Nanotechnology, targeted delivery systems, and immunomodulatory strategies are also being discussed. Regarding safety profiles and commercialization aspects, this chapter attempts to understand the current market scenario and prospects for mucosal delivery platforms. This overview aims to promote advances in drug delivery technologies and improve healthcare outcomes by connecting the gap between mucosal delivery and mucosal immunity.

Keywords: Enzymatic degradation, Immunogenicity, Innate lymphoid cells, Mucosal drug delivery, Mucosa-associated lymphoid tissue, Mucociliary clearance, Nasal mucosa, Oral mucosa, Ocular mucosa, Pulmonary mucosa, Rectal mucosa, Vaginal mucosa.

* **Corresponding author Sudhir Kumar:** Faculty of Pharmaceutical Sciences, DAV University, Jalandhar, Punjab, India; E-mail: sudhirkumar1211@gmail.com

INTRODUCTION

Drug delivery is a field that has witnessed numerous advancements in recent years. Mucosal drug delivery systems, which include different types of formulations and technologies, have emerged as one of the most promising approaches to drug administration. Such platforms are designed specifically for easier and more effective ways of getting drugs delivered through mucosal surfaces such as oral, nasal, pulmonary, vaginal, rectal, and ocular mucosa. The development of these systems came about due to growing awareness of some benefits of the mucosal route, such as enhancement in drug absorption rates, fast onset of effect, and improved patient compliance. By exploiting the porous properties of mucosae and circumventing challenges like first-pass metabolism or systemic toxicities witnessed by conventional routes of administration, new paradigms in drug delivery can be actualized through this method [1, 2].

The significance of mucosal delivery in drug administration must be emphasized. It is different from traditional methods such as oral ingestion or intravenous injection since it provides access to systemic circulation through highly vascularized and large mucosal surfaces. By so doing, absorption becomes more effective because drugs can move directly into the blood system. Besides this, there are times when a conventional route might not work at all, like in cases where drugs should be delivered to inaccessible parts of the body or on the other side of barriers such as the blood-brain barrier [3].

Mucosal delivery platforms' efficacy depends on understanding mucosal immunity and its complicated mechanisms. Mucosal surfaces are passive pathways through which drugs are absorbed and are a dynamic territory with a complex immune system. The mucosal immune system is the first line of defense against pathogens, toxins, and any other foreign invaders and thus helps to maintain tissue homeostasis and prevent infection. Immune responses in mucosal tissues are coordinated by specialized immune cells (epithelial cells, dendritic cells, T cells, innate lymphoid cells) adapted to their unique microenvironments [4].

Besides local defense mechanisms, mucosal immunity exhibits generalized systemic effects that affect immune responses. Applying these principles of mucosal immunity can help researchers develop ways to enhance the effectiveness and safety of such delivery platforms. Incorporating mucosal immunology into drug delivery design offers enormous opportunities to develop therapeutic interventions in different medical areas, from vaccination and immunotherapy to inflammatory conditions, infectious diseases, or cancer treatment [5, 6].

CONVENTIONAL VS. NOVEL APPROACHES FOR MUCOSAL DELIVERY

Common practices involved in mucosal drug delivery are usually based on standardized procedures like oral tablets, nasal sprays, suppositories, or vaginal creams. Although well-known and considered standard practices, they come with challenges such as poor drug bioavailability, enzyme degradation, and differing absorption rates over different membranes. More so, it may not cater to specific administration and controlled release of drugs [7].

In contrast, novel mucosal delivery techniques use advanced technologies and creative formulations to overcome these shortcomings. One such approach is nanotechnology, where nanoparticles and nanocarriers are engineered to encapsulate drugs, shield them from degradation, and enhance their transport across mucosal barriers. Particular characteristics like mucoadhesion, controlled release, and targeted delivery can be designed to improve drug delivery efficiency and accuracy to mucosal tissues [8].

In addition, innovative techniques might include mucoadhesive plus permeation-enhancing formulations that enhance drug retention and absorption at mucosal surfaces. For example, mucoadhesive hydrogels stick to mucosal tissues after they are used, elongating the drug duration in the body and enhancing their absorption. Conversely, these enhancers open temporary channels that let drugs cross the mucous membrane barriers and through epithelial membranes.

In addition, novel approaches have come up *via* the conjugation of drugs and prodrugs that will aid in mucosal drug delivery. By developing prodrug formulations or conjugating drugs with targeting ligands, researchers can develop better drug stability, tissue specificity, and less off-target effects. This will improve therapeutic outcomes [9].

Although traditional methods of delivering drugs to mucosal membranes are restricted in their scope, novel methodologies provide a promising solution that likely includes enhanced drug bioavailability, target-specific tissues, and better patient outcomes. This innovative approach has the potential to revolutionize drug delivery paradigms and meet unaddressed health gaps across various therapeutic areas through continuous research and innovation [10].

TYPES OF MUCOSAL SURFACES

Mucosal surfaces are the moist linings that cover different cavities and organs of the body, acting as boundaries between the external environment and internal tissues. Special features that make up these regions define their anatomical and

CHAPTER 2

Nasal Vaccination: Breaking New Ground in Immune Response

Akhil Sharma¹, Shaweta Sharma², Akanksha Sharma¹, Anila Mishra³ and Pankaj Agrawal^{4,*}

¹ R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

² School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

³ Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow Campus, Near Malhaur Rly Station, P.O. Chinchhat, Lucknow, U. P., 226028, India

⁴ Guru Gobind Singh Indraprastha University, Govt of NCT of Delhi, Sector 16C, Dwarka, New Delhi, 110078, India

Abstract: Among the most far-reaching strides, nasal vaccination promises to augment immune responses against numerous pathogens. The present abstract investigates how nasal vaccination has been able to change the strategies of immunization as well as pave the way for immune response modulation. In the past, vaccination mainly focused on systemic immunity through injection-based routes. However, Nasal-Associated Lymphoid Tissue (NALT), which consists of specialized tissues and abundant immune cells, offers an exclusive route for both mucosal and systemic immunity induction *via* the ventilation channel of our bodies, *i.e.*, the nose. This dual role in immune stimulation renders nasal vaccination an attractive means to counter various infectious diseases, such as respiratory viruses like influenza and new pathogens like SARS-Co-2. The nasal vaccine has several benefits. One of them is that it is administered without needles, thus reducing the fear and discomfort connected with injection, which enhances patient compliance, especially in pediatrics and needle-phobic people. Secondly, nasal vaccination utilizes local immune responses through a mucosal immune system where it induces robust secretory IgA antibodies as a first line of defense against mucosal pathogens. Besides, nasal vaccines may also cause systemic immunity so that protection is not limited to mucosal surfaces. Nasal vaccines have been developed into different types, including live attenuated and inactivated vaccines, as well as newer platforms like subunit vaccines and DNA-based formulations. All these have their advantages and disadvantages; hence, each pathogen or targeted population should be dealt with separately. However, nasal vaccination has numerous challenges to overcome. These include stability, formulating the vaccines into standardized forms that can be used regularly, and how to regulate these vaccines. It is

* Corresponding author Pankaj Agrawal: Guru Gobind Singh Indraprastha University, Govt of NCT of Delhi, Sector 16C, Dwarka, New Delhi, 110078, India; E-mail: pankajggsipu@gmail.com

necessary to address these issues to allow nasal vaccination's maximum utility in public health intervention. The way forward is ongoing research to improve the formulation of nasal vaccines, optimize delivery systems, and introduce new adjuvants for better efficacy against the existing constraints. In addition, personalized medicine can facilitate the customization of nasal vaccines based on individual immune profiles, which enhances their effectiveness greatly. Overall, nasal immunization strategies are a paradigm shift from traditional approaches since they represent a versatile and effective means of concurrently generating protective immunity against multiple pathogens. Therefore, exploiting its unique features while addressing current limitations associated with nasal vaccination can open up new frontiers in modulating immune responses besides enhancing global health outcomes.

Keywords: Immune response, Mucosal immunity, Needle-free administration, Nasal vaccination, Personalized medicine, Secretory immunoglobulin A (IgA), Vaccine formulations.

INTRODUCTION

Intranasal vaccination, also called nasal vaccination, is when vaccines are administered through the nose rather than by injection. This method uses the mucosal immune system present in the nasal cavity to trigger a defensive response against particular pathogens, similar to typical vaccines that alert the body's immune system to identify and destroy pathogens [1].

Nasal vaccines usually include weakened or dead forms of the desired pathogen, surface proteins on the same, or genetic material that encodes these proteins. When the vaccine is given intranasally, it reacts with the mucosal lining, and then antibody production and immune cells such as T cells and B cells get activated. This particular immunity response makes the body recognize and respond to attacks by pathogens, hence preventing infection [2].

There are various advantages of nasal vaccination compared with conventional injection-based methods, such as ease of administration, the potential for needle-free delivery, improved mucosal immunity, and the ability to evoke both systemic and local immune responses. This method has been investigated against infectious diseases, including influenza, measles, polio, and COVID-19, which may help increase vaccine uptake and efficiency [3].

It is a cornerstone of immunological progress, with profound implications for building defenses against a range of infectious diseases. Positioned at the intersection of mucosal immunity, this new technique effectively uses the network of mucosal surfaces inside the nasal cavity to generate a robust immune response. By using this first-line defense, nasal vaccination blocks invasive pathogens right at their entry points. It provides an obstacle that prevents infection while also

preparing the body's immune system for quick and specific retaliation. This local defense process strengthens the initial body's line of defense and acts as a sentinel, monitoring any microbial intrusion into the mucosa [4].

Nasal immunization is highly important as it arms the immune system with a double weapon that can mobilize both mucosal and systemic immunity for an overall defense against pathogens. Nose immunization creates a powerful obstruction to pathogen invasion of the mucosa through activation of mucosal immunity characterized by secretion of IgA, recruitment of specialized immune cells, production of antibodies, and other things. On top of this, when there is stimulation of systemic immune responses, there is widespread protection in which circulating antibodies are produced and T-cell activity to destroy invading pathogens, leading to lifelong protection all over the body [5].

Besides its immune system powers, the lack of a need for needles in nasal vaccination indicates that a new approach to vaccine administration facilitates greater availability and acceptance globally. Nasal vaccination, on the other hand, removes all these barriers by avoiding the agony and reluctance that come with traditional injections, hence encouraging more participation and adherence to immunization programs. Furthermore, this easy-to-use technique reduces occupational risks such as needlestick injuries, promoting safety for health workers while increasing resilience at the front lines toward infectious diseases [6].

Nasal vaccination is a key pillar of public health preparedness and response in the fire of epidemics and pandemics, offering a fast, focused intervention to suppress the spread of diseases. Nasal vaccination also provides a strong defense against disease transmission by interrupting outbreaks and avoiding disastrous results by rapidly applying focused immunization strategies at the center of viral attacks. In addition to protecting individuals against infections, nasal vaccines also stop the multiplication of viruses within communities and thus decrease their chances of spreading among people who come into contact with them because they confer mucosal immunity at pathogen entry sites [7].

Nasal immunization is a nasal spray vaccine that deviates from conventional vaccination methods and epitomizes how to combat contagious diseases with exactitude and strength. The innovation of science and strategic eyesight is demonstrated in nasal immunization, making it the next frontier in global health delivery that will enhance population preparedness to deal with new strains of pathogens, which have never been witnessed before, effectively and resiliently [8].

CHAPTER 3

Oral Vaccines: A Revolution in Preventive Medicine

Shekhar Sharma^{1,*}, Rupali Sharma², Sudhir Kumar³, Alok Bhardwaj¹ and Koushal Dhamija¹

¹ *Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India*

² *Amity University Haryana, Manesar, Gurugram, India*

³ *Faculty of Pharmaceutical Sciences, DAV University, Jalandhar, India*

Abstract: The development and widespread implementation of oral vaccines have marked a significant milestone in preventive medicine, offering a revolutionary approach to combat infectious diseases. Unlike traditional injectable vaccines, oral vaccines are administered through the oral route, making them more accessible and easier to distribute, particularly in resource-limited settings. This chapter discusses the transformative impact of oral vaccines on disease prevention, highlighting their advantages, challenges, and prospects. The efficacy of oral vaccines is related to their ease of administration, eliminating the need for needles and trained healthcare personnel, which can be barriers in certain populations. This feature enhances vaccine acceptance and coverage, especially in regions with limited healthcare infrastructure. Moreover, oral vaccines stimulate mucosal immunity at the site of pathogen entry, providing an additional layer of protection against infectious agents transmitted through mucosal surfaces, such as the gastrointestinal and respiratory tracts. Several oral vaccines have been developed to target a range of infectious diseases, including polio, rotavirus, and cholera. The success of oral polio vaccine campaigns, for instance, has led to the near eradication of poliovirus in many parts of the world. Similarly, oral rotavirus vaccines have significantly reduced the burden of diarrheal diseases, particularly in children under five years old, in both developed and developing countries. Vaccine safety and efficacy concerns remain subject to ongoing research and development efforts. Overcoming these challenges requires interdisciplinary collaboration among scientists, clinicians, and policymakers to optimize vaccine formulations, delivery strategies, and regulatory frameworks. In conclusion, oral vaccines represent a paradigm shift in preventive medicine, offering a potent tool to combat infectious diseases globally. Continued research, innovation, and investment in

* **Corresponding author Shekhar Sharma:** Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India;
E-mail: shekharsharma1981@gmail.com

oral vaccine development and delivery platforms are essential to realizing their full potential and ensuring equitable access to life-saving immunization strategies worldwide.

Keywords: Cholera, Diarrhea, Infectious diseases, Infectious agents, Mucosal surface, Oral drug delivery, Oral vaccine, Polio, Rotavirus, Typhoid.

INTRODUCTION

Oral vaccines represent a category of vaccines that are administered *via* the oral route, typically in the form of liquid drops, tablets, or capsules. Unlike traditional injectable vaccines, delivered *via* intramuscular or subcutaneous injection, oral vaccines are ingested, allowing the vaccine antigen to interact directly with mucosal surfaces in the gastrointestinal tract. These vaccines induce protective immune responses at mucosal sites, such as the intestines and respiratory tract, where many pathogens enter the body. By stimulating mucosal immunity, oral vaccines can prevent infections or reduce their severity by blocking the entry and replication of pathogens at their primary point of invasion [1, 2].

The development of oral vaccines has significantly improved immunization strategies, particularly for diseases that primarily affect mucosal surfaces, such as polio, rotavirus, cholera, and typhoid fever. For example, oral polio vaccines (OPV) contain weakened forms of the poliovirus that stimulate immune responses in the gastrointestinal tract, protecting against poliovirus infection. Oral vaccines offer several advantages over injectable vaccines, including simplified administration, increased patient compliance, and reduced dependence on trained healthcare personnel. They are particularly well-suited for mass vaccination campaigns in resource-limited settings, where access to healthcare infrastructure and trained personnel may be limited [3, 4].

Oral vaccines also present unique challenges, such as ensuring vaccine stability in the harsh environment of the gastrointestinal tract and optimizing vaccine delivery to maximize immunogenicity. Despite these challenges, oral vaccines have played a crucial role in global disease control and eradication efforts, demonstrating their potential to prevent infectious diseases and improve public health worldwide [5].

Vaccines are one of the most powerful tools in preventive medicine, offering protection against a wide range of infectious diseases. Their importance cannot be overstated, as they have played a pivotal role in reducing the burden of infectious diseases, preventing millions of deaths, and improving public health worldwide. Vaccines stimulate the immune system to recognize and defend against specific pathogens, such as viruses and bacteria, before they can cause disease. By triggering an immune response, vaccines prime the body to mount a rapid and

effective defense if exposed to the actual infectious agent. This preemptive immunity is crucial for preventing the spread of contagious diseases within communities and reducing the likelihood of outbreaks [6, 7].

Vaccines have been instrumental in eradicating or controlling several devastating diseases. For example, the global eradication of smallpox, achieved through widespread vaccination campaigns, is one of the greatest triumphs in public health history. Similarly, vaccines have dramatically reduced the incidence of polio, measles, rubella, and other once-common diseases, bringing them under control in many parts of the world [8].

Vaccines provide crucial protection for vulnerable populations, including infants, young children, older people, and individuals with weakened immune systems. Immunization during early childhood helps safeguard children from serious and potentially life-threatening infections, while vaccination of older adults helps prevent complications from diseases such as influenza and pneumococcal infections. Vaccination during pregnancy can confer passive immunity to newborns, offering protection during the vulnerable early months of life [9].

Vaccines not only protect individuals who receive them but also contribute to the concept of herd immunity. When a significant portion of the population is immune to disease through vaccination, it creates a collective barrier that limits the pathogen's spread, thereby protecting those who cannot be vaccinated due to medical reasons or age. Herd immunity is particularly important for safeguarding vulnerable individuals and preventing outbreaks, especially for diseases with high transmission rates [10].

Vaccines are among the most cost-effective interventions in public health. The economic benefits of vaccination programs far outweigh the costs, as they prevent illness, hospitalizations, and premature deaths, resulting in substantial savings in healthcare expenditures and productivity losses. Moreover, investing in vaccination programs can yield long-term dividends by averting the need for costly treatments and mitigating the socioeconomic impact of disease outbreaks [11, 12].

Vaccines are crucial in strengthening global health security by mitigating the risk of pandemics and emerging infectious threats. Through international collaboration and coordinated vaccination efforts, diseases such as influenza, Ebola, and COVID-19 can be controlled and contained, preventing their spread across borders and reducing the potential for widespread morbidity and mortality. Table 1 summarizes the brief history of vaccines.

CHAPTER 4

Pulmonary Vaccination: Inhalable Solutions for Respiratory Diseases

Akhil Sharma¹, Shaweta Sharma², Mobeen Shaik³, Hrithik Dey⁴ and Pankaj Agrawal^{5,*}

¹ R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

² School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

³ KL College of Pharmacy, Koneru Lakshmaiah Education Foundation (Deemed to be University), Andhra Pradesh, India

⁴ Lloyd Institute of Management & Technology, Plot No.-11, Knowledge Park-II, Greater Noida, Uttar Pradesh-201306, India

⁵ Guru Gobind Singh Indraprastha University, Govt of NCT of Delhi, Dwarka, New Delhi, India

Abstract: Influenza viruses, SARS-CoV-2, and mycobacterium tuberculosis are some of the deadly microbes that continue to make it difficult for us to deal with health problems globally. Although there is a wide range of treatment options for respiratory diseases, including influenza, COVID-19, or tuberculosis, traditional vaccines such as oral formulations and injections have limitations in effectively targeting these pathogens. However, the solution to this challenge lies in the development of inhalable vaccines. Inhalable vaccines take advantage of infection through respiration, thus allowing for pathogens that cause diseases through the mouth and nose. This chapter discusses the possible role of inhalable vaccines in transforming or solving issues related to respiratory diseases. Compared to traditional vaccination methods, inhalable vaccines have several advantages. Inhalable vaccines replicate natural infection routes, which helps provoke both systemic and mucosal immune responses, thereby improving immunity at the pathogen entry points. Several delivery strategies have been developed for optimal vaccine administration into the lungs, including dry powder formulations and aerosols. Moreover, inhalable vaccines facilitate simplified administration, which may enhance vaccine coverage rates in resource-poor settings where compliance is an issue. Some inhalable vaccines are being developed or tested for respiratory problems, including flu, COVID-19, and tuberculosis. These vaccines show remarkable effectiveness and safety records to make their mass distribution possible. However, there are still challenges, such as the requirement for strong delivery systems to administer the right amount of vaccine and keep the vaccine formulations stable. The

* **Corresponding author Pankaj Agrawal:** Guru Gobind Singh Indraprastha University, Govt of NCT of Delhi, Dwarka, New Delhi, India; E-mail: pankajggsipu@gmail.com

approval and distribution of inhalable vaccines depend on various factors, including safety issues related to their administration *via* the pulmonary route and regulatory requirements. In the future, this new type of vaccine can revolutionize respiratory disease control. More research and developments are needed to make inhalable vaccines more efficient, safer, and accessible. Thus, if we take advantage of the potential of vaccination through the lungs, we can start moving towards a world where respiratory diseases are prevented globally.

Keywords: Aerosols, COVID-19, Dry powder, Influenza, Inhalable vaccines, Pulmonary vaccination, Respiratory disease, Tuberculosis, Viruses.

INTRODUCTION

Millions of people die due to respiratory diseases every year, and this is a huge public health issue worldwide with significant economic costs. This has led to the discovery of pathogens like influenza viruses, respiratory syncytial virus (RSV), tuberculosis bacilli, and, most recently, novel coronaviruses that have prompted vaccination strategies to prevent and control such infections. Even though traditional types of vaccines effectively reduce the burden imposed by infectious diseases, they may have limited efficacy towards respiratory pathogens because some factors may hinder complete protection on mucosal surfaces and necessitate regular booster doses [1].

In this context, pulmonary vaccination is a promising option to tackle respiratory diseases by directly targeting the mucosal surfaces of the respiratory tract where various pathogens begin an infection. Unlike traditional routes of vaccination that mainly evoke systemic immune responses, pulmonary vaccination exploits exceptional immunologic features of the respiratory mucosa to generate local and systematic immunity. The resulting dual immune activation makes a vaccine highly efficient in preventing infection and decreasing disease severity [2].

Compared to conventional methods, pulmonary vaccination has several major benefits. Pulmonary vaccination can elicit strong mucosal immune reactions, such as the production of secretory IgA antibodies that neutralize and clear pathogens at the site of entry. Besides this, pulmonary vaccination prompts system-wide immune responses to safeguard against respiratory pathogens more broadly and decrease the likelihood of disease transmission in a community [3].

Furthermore, pulmonary immunization has its own advantages, just like needle-free administration, which could enhance vaccine uptake and compliance, especially among those who fear the use of needles or are hesitant to receive vaccines. Additionally, the noninvasive method of vaccination holds promise for

needle-free mass vaccination programs, particularly in emergencies such as pandemics or outbreaks of highly infectious respiratory diseases [4].

The threats of respiratory disease outbreaks still exist as the globe continues to urbanize and increase its population. Within this context, it is important that efficient pulmonary vaccination strategies are developed and put in place to reduce the impact of respiratory diseases on public health. By using pulmonary vaccination techniques, we can move a step closer to eradicating respiratory diseases completely by preventing them from occurring altogether [5]. Table 1 describes the history of pulmonary vaccination and its evolution.

Table 1. History of pulmonary vaccination and its evolution.

Period	Key Developments
1960s	- Landmark research provides evidence for the effectiveness of an aerosolized vaccination against measles in activating immune systems that protect non-human primates [6].
1970s-1980s	- Exploration is constantly ongoing to find ways of giving out vaccines by inhaling. - Making nebulizers, dry powder inhalers, and pressurized metered-dose inhalers for controlled vaccine delivery [7].
1990s	- Improve vaccine compositions and adjuvant technology for better immunogenicity of inhaled vaccines. - The creation of inhaled vaccines against respiratory pathogens such as influenza viruses, RSV, and tuberculosis [8].
Present Day	- Pulmonary vaccination has regained interest because of the rise of new respiratory pathogens such as SARS-CoV-2. - Active research and development of inhalable COVID-19 vaccines to address the ongoing pandemic [9].

Challenges of Traditional Vaccination Methods

Vaccination is done using traditional means of administering injections or oral intake techniques that have been used for decades to avert the occurrence of diseases. Nevertheless, they face various obstacles, especially when dealing with respiratory tract infections. On the other hand, vaccines administered through injection may not focus on the mucus membranes where most of these infection-causing agents breed. Another aspect is that injections should be administered by qualified health practitioners; hence, it has logistics hitches, mainly in places where resources are limited or during extensive vaccination programs [10].

Apart from their convenience, oral vaccines may fail to stimulate mucosal immunity in the respiratory tract, which means that their potential efficacy against respiratory pathogens is limited. Oral vaccines nonetheless have hurdles like variable absorption and degradation in the gastrointestinal tract, which cause

CHAPTER 5

Mucosal Vaccines for Gastrointestinal Infections

Neeraj Kumar Fuloria¹, Akhil Sharma², Sunita³, Akanksha Sharma² and Shaweta Sharma^{4,*}

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AIMST University, Semeling Campus, Jalan Bedong-Semeling, Bedong, Kedah Darul Aman, Malaysia

² R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

³ Metro College of Health Sciences and Research, Greater Noida, India

⁴ School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

Abstract: Infections of the digestive system are responsible for many illnesses and deaths in all ages worldwide. Conventional ways of producing vaccines have proven inefficient at fighting these diseases, mainly because they cannot instigate mucosal defenses, which are vital in protecting the entry points against pathogens. Mucosal vaccines, meant to stimulate immune reactions on the mucus membranes, may be more effective in preventing gastrointestinal infections. The chapter gives a general idea of the current state of mucosal vaccines in gastrointestinal infections. First, we will explore the different forms of gastrointestinal infections, including bacterial, viral, and parasitic, identifying their prevalence and how they impact public health. Furthermore, we consider conventional vaccine strategies such as restricted elicitation of mucosal immune response and antibiotic resistance strains. The major role of mucosal immunity against gastrointestinal pathogens will be discussed. The chapter gives a general idea of the current state of mucosal vaccines in gastrointestinal infections. First, we will explore the different forms of gastrointestinal infections, including bacterial, viral, and parasitic, identifying their prevalence and how they impact public health. Furthermore, we consider conventional vaccine strategies such as restricted elicitation of mucosal immune response and antibiotic resistance strains. The major role of mucosal immunity against gastrointestinal pathogens will be discussed. Moreover, we have dealt with problems such as vaccine manufacture and regulation by emphasizing the ongoing research in this area. To finish, they are a better way to prevent gastrointestinal infections by using the body's defense mechanisms. Continuous investments in mucosal vaccine development and fresh ideas are highly needed to effectively address the worldwide burden of gastrointestinal ailments.

* **Corresponding author Shaweta Sharma:** School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India; E-mail: shawetasharma@galgotiasuniversity.edu.in

Keywords: Antibiotics, Gastrointestinal infection, Immunity, Pathogen, Mucosal vaccine, MALT, Secretory IgA.

INTRODUCTION

Gastrointestinal health is a term that is used to refer to the general well-being and proper working order of various digestive organs such as the stomach, intestines, liver, pancreas, and others. This concept involves efficient digestion and absorption of nutrients, balanced microbiota in the gut, effective immunity against pathogens, and lack of digestive diseases or disorders. These factors include normal bowel movements, no discomforts or pains in the stomach, maximum nutrient intake, and good gut flora. A proper functioning digestive system is essential for the general well-being of an individual since imbalances or malfunctions can lead to many gastrointestinal diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and gastrointestinal infections [1].

Gastrointestinal health is often ignored in modern medicine, yet it serves as a key requirement for good health and influences various aspects of human life significantly. The gastrointestinal tract is at the center of the body's digestive system and nutrient assimilation, which changes food into critical elements needed to live. Digestion is a process that begins in the mouth when food enters and ends up in the intestines, where it breaks down to be absorbed. Such digestive processes show how critical gastrointestinal health is for the body's access to those nutrients needed for energy generation, growth, repair, and maintenance of essential functions [2].

Apart from helping with digestion and absorption of nutrients, the digestive system harbors numerous microorganisms called gut microbiomes essential for inducing immune responses, metabolic events, and even psychological well-being. Elaborate cross-talk between the gut microbiome and the host immune system is critical in maintaining a constant internal environment, presumably against invading microbes, and suppressing inflammatory reactions that could result in long-term complications [3].

The gut microbiome acts as a sentinel, controlling immune responses against external threats and producing tolerance so that harmless antigens shape the body and thereby its capacity to fight infections and block the development of autoimmune diseases. In addition, intestinal dysbiosis, which often arises from factors like unhealthy eating habits, stress, antibiotics, and environmental pollutants, is strongly associated with the pathogenesis of numerous gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and gastroesophageal reflux disease (GERD) [4].

The idea of gastrointestinal health depends on the degree of digestive comfort, which would involve consistent bowel movements, lack of abdominal distress, bloating, and uneasiness. People who experience discomfort in their tummies are highly affected, hence leading to changes in lifestyle amongst them since their conditions vary from slight inconveniences to serious pain. Consequently, promoting gastrointestinal health not only boosts body wellness but also improves quality of life and overall satisfaction [5].

Recent research has also brought to light the complex connections between the central nervous system and the gastrointestinal tract, revealing a two-way communication network known as the gut-brain axis. It provides a pathway through which signals from the stomach affect feelings, thinking ability, and reactions to stress, thus highlighting how closely mental health is linked to our intestines. There are indeed suggestions that any disturbances in this network could contribute significantly to psychiatric conditions such as depression, anxiety, or even neurodegenerative diseases [6].

Regarding disease prevention, one of the key strategies for reducing the risk of different gastrointestinal disorders and systemic diseases with gastrointestinal ramifications is maintaining gut health. This can be achieved by establishing a diverse and robust gut microbiota, implementing diets that support digestive health, and avoiding harmful elements to their digestive system, such as drugs or other chemicals they could be exposed to. This way, people are able to instigate actions that will ensure their gut health is well taken care of and, in turn, protect overall body health [7].

Prevalence and Impact of Gastrointestinal Infections

The prevalence of gastrointestinal infections is global and affects people of all demographics and ages. Most often, these are caused by various pathogens such as bacteria, viruses, fungi, or parasites and are commonly transmitted through contaminated food or water, lack of hygiene measures, or close contact with infected persons. The consequences of gastrointestinal diseases on public health, economies, and individual welfare are numerous and varied [8].

Every year, millions of cases occur worldwide, and some pathogens cause pandemics and epidemics. Bacterial infections caused by *Salmonella*, *E. coli* (*Escherichia coli*), *Campylobacter*, and *Shigella*, as well as viral infections like rotavirus, norovirus, and hepatitis A virus, are common in gastrointestinal infections. Protozoan parasites such as *Giardia* and *Cryptosporidium* also add to the burden of gastrointestinal diseases, particularly in areas that lack good hygiene and clean water supplies [9].

CHAPTER 6

Urogenital Vaccination: Addressing STIs and Beyond

Amana Parveen¹, Shekhar Singh², Dimple Singh Tomar³, Akhil Sharma⁴ and Shaweta Sharma^{5,*}

¹ PSIT-Pranveer Singh Institute of Technology Pharmacy, Jargaon, India

² Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India

³ Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, India

⁴ R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

⁵ School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

Abstract: The emergence of urogenital vaccination as a groundbreaking approach to fight against sexually transmitted infections (STIs) and promote urogenital health is a milestone. In this chapter, preventive healthcare potential with regard to urogenital vaccination is widely explored. It begins by situating the prevalence and consequences of STIs globally in order to stress that better prevention methods are highly required. Novel strategies are needed to address the shortcomings of traditional strategies, such as condoms and behavioral interventions, that present obstacles in the way of wider adoption and effectiveness. This kind of novelty is seen in urogenital vaccination, which offers particular protection against a variety of pathogens that cause STIs, namely chlamydia, gonorrhea, and human papillomavirus (HPV). Also, it can be applied broadly to other urogenital health issues like urinary tract infections (UTIs). This chapter explores the benefits of urogenital vaccination, which include providing long-term protection and simplifying prevention activities, especially in high-risk populations. However, there are still hurdles to be overcome in developing effective vaccines for urogenital pathogens. Ethics surrounding vaccine safety, efficacy, and equitable availability should also be considered for successful implementation. Public health can be transformed by urogenital immunizations, which would lower the transmission rates, reduce the burden linked to STIs, and improve urogenital health outcomes. Nevertheless, long-term research on investment strategies, integration with existing sexual health programs, and sexually transmitted infection (STI) prevention is required in order to achieve these advantages. This chapter demands more cooperation

* **Corresponding author Shaweta Sharma:** School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India; E-mail: shawetasharma@galgotiasuniversity.edu.in

and dedication to realize the full potential of urogenital vaccination as an important preventive mechanism in medicine, as well as healthier lives for individuals and societies all over the world.

Keywords: Chlamydia, Gonorrhea, Healthcare, Human papillomavirus, Sexually transmitted infections, Urinary tract infections, Urogenital vaccine.

INTRODUCTION

Urogenital immunization and sexually transmitted infections (STIs) have recently become important elements in preventive healthcare. Urogenital vaccination involves the development and administration of vaccines specifically targeting pathogens that affect the urogenital tract, including viruses and bacteria responsible for STIs, such as chlamydia, gonorrhea, and human papillomavirus (HPV). These vaccines have the purpose of producing defensive immunity against these pathogens in order to prevent an attack and lessen the incidence of sexually transmitted infections. STIs are diseases that are mainly spread through sexual contact. They pose substantial public health problems for people around the world because they are common, affect personal well-being, and attract social disgrace. Examples include chlamydia, gonorrhea, syphilis, HPV, herpes simplex virus (HSV), and HIV [1, 2].

It is a promising strategy to introduce urogenital vaccination in the fight against STIs, offering targeted protection against specific pathogens that cause these infections. Vaccines can help prevent urogenital pathogen infections, reduce the risk of infection, and aid overall urogenital health by strengthening immunity against them. Urogenital vaccination may be used to augment already existing preventive measures like condom use and regular testing, allowing for an extra layer of protection from STIs [3]. Advancements in these studies have the potential to totally transform STI prevention strategies and improve the urogenital health of individuals and communities across the world. The significance of urogenital vaccination in preventing STIs and other urogenital health concerns is described below and summarized in Fig. (1).

Targeted Protection

Urogenital vaccines are meant to be revolutionary in the fight against STIs as they directly focus on organisms that cause these infections, like chlamydia, gonorrhea, and HPV, among others. Rather than general measures of protection such as condoms, urogenital vaccines sensitize the immune system to identify and respond directly to these pathogens. Vaccines are usually developed to contain nonpathogenic parts of the pathogens or their antigens that, when introduced into

the body, stimulate antibody production and memory cells, which can quickly recognize and neutralize real infectious agents whenever they invade the body [4].




Fig. (1). Significance of urogenital vaccination in preventing stis.

The targeted protection boosts the body's ability to resist further infections by lowering transmission risk and minimizing complications due to STIs. Moreover, urogenital vaccines concentrate on particular pathogens causing STIs and thereby have a more customized and efficient preventive approach that would supplement already existing strategies and may, therefore, help ease the public health STI burden in general [5].

Reducing Transmission Rates

Urogenital immunization is important in reducing STI transmission among communities by targeting the causative pathogens of such infections. Vaccinating individuals with specific STI-causing agents not only protects such individuals but also helps to build wider community immunity. Vaccination reduces the number of infected individuals in a community. Thus, so-called "herd immunity" takes place, and it prevents the transmission of targeted STIs. Consequently, even unvaccinated persons, who may include those who cannot be immunized because

Mucosal Vaccination in Pediatric Medicine

Ashish Srivastava¹, Shekhar Singh², Dimple Singh Tomar³, Shaweta Sharma⁴ and Akhil Sharma^{5,*}

¹ PSIT -Pranveer Singh Institute of Technology Pharmacy, Jargaon, India

² Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India

³ Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, India

⁴ School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

⁵ R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

Abstract: In the field of pediatric medicine, mucosal vaccination has come into view as a game changer with regard to the prevention of infectious diseases among children. This chapter thoroughly discusses recent developments, challenges, and future prospects of mucosal vaccination in pediatric population. It also starts by explaining the peculiarities of mucosal immunity in children while emphasizing the significance of aiming at these surfaces for vaccine delivery. It also looks at the varied benefits that come with mucosal vaccines, such as their ability to provoke robust immune responses both locally and systemically, be given without using a needle, and fight against the infections mentioned above most effectively, which is very significant for young children. Besides, the chapter provides an extensive overview of the current status of mucosal vaccines in relation to pediatric infectious illnesses targeting respiratory system infections, gastrointestinal ailments, and sexually transmitted diseases. This chapter provides insight into the clinical relevance and potential impact of mucosal vaccination on pediatric healthcare practice. It does this by analyzing recent developments in mucosal vaccine research and clinical trials aimed at combating common childhood infections such as influenza, rotavirus, pneumococcus, and human papillomavirus (HPV). However, despite the possibility of mucosal vaccination, this chapter also highlights a number of problems that need to be overcome in order to exploit its advantages fully. These encompass vaccine formulation and delivery issues, regulatory affairs, public acceptance of the technology, and healthcare infrastructure. However, the section ends on an optimistic note by discussing future research directions and strategies for overcoming these challenges. New methods of immunizing, a composition containing adjuvants, substances capable of increasing mucosal adherence, and modern means of administering a drug are some other areas that have been investigated. Finally, the use of mucosal vaccines represents the light at

* **Corresponding author Akhil Sharma:** R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India; E-mail: xs2akhil@gmail.com

the end of the tunnel in treating children's diseases, as it offers hope for decreasing infectious diseases and alleviating children's suffering across the globe. We can, therefore, use the transformative effect of mucosal vaccination and ensure the equal distribution of life-saving vaccines for all children, ushering in a new era of pediatric health by promoting cooperation among academia, industry, healthcare providers, and policymakers.

Keywords: Chlamydia, Gonorrhea, Human papillomavirus, Healthcare, Sexually transmitted infections, Urinary tract infections, Urogenital vaccine.

INTRODUCTION

Mucosal immunization is a novel, path-breaking way to approach the field of immunization, thereby changing entirely how infectious diseases are protected against. It aims at mucosal surfaces, namely respiratory, gastrointestinal, and urogenital tracts, through which many pathogens get into our bodies. Unlike traditional vaccinations, which are more commonly given by injection, mucosal vaccinations are administered through other routes such as oral routes (like ingestion), nasal routes (through sprays), and finally, pulmonary inhalation, among others [1].

There are several advantages of mucosal vaccination. It is able to directly activate immunity at the infection site where pathogens start infecting. Vaccines that target the immune system in mucous membranes can be used effectively to hinder or prevent the entry and global dissemination of pathogens, which would otherwise lead to the establishment of disease. In addition, this localized immune activation stimulates systemic immunity, thus increasing body defense mechanisms against invasions by microbes [2].

Furthermore, mucosal vaccines have displayed the potential to induce a broader array of immune replies than standard vaccines. They can induce both mucosal immune responses, comprising the activation of specialized immune cells and the production of secretory antibodies at the mucosal surfaces, and systemic immunity, which entails the secretion of circulating antibodies and mobilization of T cells across the whole body. This dual effect boosts the overall efficacy of the vaccine and protects against all sorts of infections [3].

Another significant advantage of mucosal immunization is that it can be given without a needle, making easy the delivery of vaccines and allowing their wide spread use in immunizing people in large communities living in areas where resources are scarce. Mucosal vaccines provide a more user-friendly and less intrusive option by doing away with needles and syringes, thereby possibly enhancing patient acquiescence and adherence [4].

In addition, mucosal surfaces are enriched in unique types of immune cells and tissues collectively known as mucosa-associated lymphoid tissue (MALT), which consist of organs such as tonsils, adenoids, Peyer's patches situated in the intestines, and bronchial-associated lymphoid tissue (BALT) in the respiratory tract. MALT is important for starting up immune reactions against pathogens met at mucosal surfaces, governing the making of immunoglobulin A (IgA) antibodies for secretion while also activating T-cells and dendritic cells to provide instant protection [5].

Mucosal vaccination is a broad area of research and development, and as such, it has numerous possibilities for combating different types of infections, including respiratory pathogens like influenza and coronaviruses that cause COVID-19, gastrointestinal ones such as rotavirus and norovirus, and sexually transmitted ones, for instance, HPV. This makes them especially useful as vaccines since they have several advantages over other forms of medication, such as their efficacy, convenience to patients' lives, and global health transformation opportunities that could generate new ideas about the purpose of immunizations in the future [6].

Importance in Pediatric Medicine

The establishment of all pediatric medical practices makes use of mucosal vaccination in the fight against many diseases caused by infections, which is a very good thing because children's immune systems are more complicated than those of adults. Infants and small children have immune systems that are still growing and might not work as effectively as expected with common immunizations. The major routes of transmission for diseases like flu, diarrhea, and pneumonia, which are frequently caused by different pathogens, are the mucous membranes like those present in the digestive and respiratory systems. Immunization successfully stops early intervention, especially when the mucosa is targeted. This is due to the fact that vaccines developed to stimulate immune responses at the site of pathogen entry can prevent infection before it fully establishes itself [7].

As an important advantage in pediatric medicine, mucosal vaccination can activate both local and systemic immune responses. Secreting IgA antibodies, which are produced by the mucosal surfaces, is one of the local immune responses that help neutralize pathogens before tissue invasion and systemic infection. Systemic immunity is produced by the mucosal vaccines that, at the same time, start to synthesize blood antibodies and T memory cells and offer more and better protection to all body organs. The prevention of infections from happening in the mucosal entry sites is not the only reason for using this method. It also reduces the

CHAPTER 8

Immunosenescence and Mucosal Vaccination in the Elderly Patients

Parul Srivastava¹, Shekhar Singh², Dimple Singh Tomar³, Shaweta Sharma⁴ and Akhil Sharma^{5,*}

¹ PSIT -Pranveer Singh Institute of Technology Pharmacy, Jargaon, India

² Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow, Uttar Pradesh, India

³ Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, India

⁴ School of Medical and Allied Sciences, Galgotias University, Yamuna Expressway, Gautam Buddha Nagar, Uttar Pradesh-201310, India

⁵ R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India

Abstract: Immunosenescence, a decline in immune function that occurs with age, is a major hurdle to successful vaccination in older people. In this chapter, the relationship between immunosenescence and mucosal vaccination is investigated, highlighting fresh approaches to improving immune protection in older adults. Dramatic changes take place in the immune system when individuals grow older, as it undergoes reduced T cell functioning and B cell responses that impede and dysregulated inflammatory processes. With these changes, vaccines become less effective, and old people become more susceptible to infections. Traditional parenteral vaccines often do not produce strong immune responses in this group, so vaccine efficacy needs to be improved through different means. For instance, mucosal vaccination could be a solution to overcome immunosenescence-induced obstacles. Mucosal vaccines induce local and systemic immune reactions by targeting the respiratory tracts and alimentary canal. As such, they have the potential to offer wider protection from respiratory pathogens. This abstract examines the mechanisms of mucosal vaccinations and their potential to induce strong immunity even in older individuals who are susceptible to diseases. Clinical research has demonstrated that immunization using this method is effective among older adults, thereby proving that it is better than most traditional injections in particular instances. However, there are still obstacles, such as how to administer these vaccines safely and regulatory aspects, which calls for more investigation and creativity in this area. The promise of elevating immunization protection in old people is achieved by the integration of mucosal vaccination into geriatric healthcare practices. By using specific vaccine strategies for addressing Immunosenescence, healthcare pro-

* **Corresponding author Akhil Sharma:** R. J. College of Pharmacy, 2HVJ+567, Raipur, Gharbara, Tappal, Khair, Uttar Pradesh 202165, India; E-mail: xs2akhil@gmail.com

viders can reduce the prevalence of vaccine-preventable diseases and improve overall health outcomes in aged populations. To sum it up, this abstract emphasizes the need to understand immunosenescence and assesses mucosal vaccination as a way to fill an immunity gap among elderly patients. In research, policy, and clinical practice collaborations, we can make headways toward a future where immunity is not restricted by age.

Keywords: Antibody, Adaptive response, B-cell, Dysregulation, Elderly patients, Mucosal vaccination, Immune system, Inflammation, Immunosenescence, Infections, Parenteral vaccine, Respiratory pathogens, T-cell.

INTRODUCTION

Immunosenescence is the age-related degeneration of the immune system. It is marked by a general decrease in the immune system's operation, which incorporates variations in the composition and role of immune cells, changes in cytokine production, and poor responses to pathogens or vaccines. Immunosenescence can heighten susceptibility to infections, weaken vaccine efficacy, and boost rates of autoimmune diseases and cancer among elderly people [1].

This is achieved through a complex and multidimensional process that is influenced by intrinsic factors, such as genetic predisposition and cellular senescence, and extrinsic factors, which include chronic inflammation, oxidative stress, and exposure to environmental pathogens over time. The elderly population needs to develop strategies for maintaining immune function and health outcomes by understanding immunosenescence [2].

The reason why understanding immunosenescence among elderly patients is so important is because it has implications for their health, the incidence of diseases that they are prone to, and the efficiency of vaccines among them. Because of the changes that occur in individuals' immune systems as they age, which, when taken together, are known as immunosenescence, their ability to produce effective immune responses against pathogens and vaccination decreases [3].

An important reason to understand immunosenescence among elderly patients is that it raises the possibility of increased risk of infection. Immunosenescence leads to changes in immune system structure and function, including thymic involution, lower T-cell diversity, and phagocytic activity impairment that reduces the resistance against pathogens. As a result, aging populations have increased vulnerability to different types of infections like pneumonia, urinary tract infections, and influenza, leading to higher rates of morbidity and mortality than younger age groups [4].

In addition, vaccine effectiveness in the elderly is also inhibited by immunosenescence. Immunization is very important for reducing disease and preventing communicable infections in aged adults. Nevertheless, its efficacy may be affected in older persons due to immune senescence-related alterations such as reduced production of antibodies, T-cell dysfunction, and decreased immunity memory. It is a significant public health challenge, especially in light of emerging infectious diseases and vaccine-preventable diseases [5].

Also, having implications for managing chronic inflammatory conditions and autoimmune diseases prevalent among the elderly, comprehension of immunosenescence is imperative. Inflammatory exacerbation and immune dysfunction related to aging may worsen diseases such as rheumatoid arthritis, inflammatory bowel disease (IBD), and atherosclerosis. Therefore, targeting immunosenescence by interventions can provide novel therapeutic approaches for the management of chronic inflammatory disorders in old patients [6].

Personalized healthcare approaches that reflect the individual immune profiles of the elderly are critical and require a deep understanding of immunosenescence. This helps to identify biomarkers for immune aging, facilitates evaluation of susceptibility to infection and response to vaccination, and enables health care providers to intervene optimally to improve immunological function and increase health outcomes of elderly patients [7].

It is important to comprehend immunosenescence among aged patients when it comes to dealing with immune function changes that are related to age, improving immunity after vaccination, handling long-lasting diseases associated with inflammation, and personalized healthcare interventions. By demystifying the intricacies of immunosenescence, scientists and health practitioners can create a chance for modern tactics toward healthy aging as well as better life standards among older people [8].

UNDERSTANDING IMMUNOSENESCENCE

Age-Related Changes in the Immune System

Immunosenescence encompasses age-related changes in the immune system that significantly impact health and illness among older adults. As they age, people's immune systems undergo both anatomical and functional transformations that affect cellular construction, signaling pathways, and inflammatory reactions [9].

The aging immune system is known for thymic involution, which causes a progressive decrease in the size and function of the thymus gland responsible for T-cell production. The ability of the immune system to fight new pathogens and

SUBJECT INDEX

A

- Acute respiratory distress syndrome (ARDS) 111, 120
- Adaptive immunity 1, 11, 12, 13, 160, 246, 248, 252
- Adenoids 208, 210
- Adenovirus 48, 51, 150
- Adjuvants 56, 57, 58, 68, 187, 188, 193, 195, 264
 - customized 57
 - innovative 58, 264
 - novel 68, 187, 188, 193
 - use of 56, 195
- Aerosols 106, 107, 123, 125, 126
- Agents 9, 11, 12, 20, 23, 25, 40, 47, 93, 108, 115, 142, 143, 144, 156, 158, 214, 249, 256
 - bacterial 47
 - bacteriological diarrheal 214
 - causative 142, 143, 144
 - disease-causing 11
 - immune-modulating 23
 - immunomodulatory 23
 - immunosuppressive 115
 - infection-causing 108, 249
 - mucosal 256
 - pathogenic 12, 40
 - safer antiparasitic 158
 - stabilizing 93
 - systemic 20
 - therapeutic 9, 25
 - topical antifungal 156
- Agglutination 163
- Amoebic dysentery 153
- Antibodies 8, 37, 48, 52, 80, 85, 115, 124, 162, 207, 211, 212, 215, 221, 228, 245, 249, 250, 259
 - circulating 37, 124, 207, 221
 - cross-reactive 259
 - effective 245
 - high-affinity 162
 - monoclonal 115
 - mother's 52
 - pathogen-fighting 249
 - producing 8, 80, 85
 - secretory 207, 212
 - sensitive 250
 - surface-bound 48
 - systemic 211, 215
 - transferring 228
- Antigen 8, 12, 15, 16, 17, 41, 42, 43, 48, 49, 56, 79, 80, 91, 92, 94, 125, 126, 131, 160, 162, 187, 193, 211, 260, 262, 264
 - delivery 187, 262
 - enhancing targeted 131
 - targeted 94, 187
 - exposure 126
 - expression 92
 - fragments 80
 - presentation 12, 15, 16, 49, 56, 91
 - presentation facilitation 125
 - presenting cells, specialized 15, 211
 - quantification 56
 - receptors 17
 - sampling 8, 41, 42, 43, 162
 - sampling 160
 - selection 264
 - stability 91
 - uptake 48, 79, 92, 193, 260
- APCs (antigen-presenting cells) 41, 42, 43, 48, 49, 54, 80, 126, 215, 255, 260

B

- BALT (bronchial-associated lymphoid tissue) 208, 210
- Bordetella pertussis* 47, 51, 72, 228

C

- C. difficile* infection (CDI) 148
- C-reactive protein (CRP) 250
- Campylobacter* 145, 146

coli 145
 infections 145, 146
jejuni 145
 species 145
 transmission 145
Candida albicans 155, 156
 Cervical cancer 52, 55, 72, 176, 179, 190, 197
 Chimpanzee adenovirus vector 73
Chlamydia trachomatis 188
 Cholera 51, 52, 55, 58, 64, 65, 68, 87, 88, 94, 95, 147
Clostridium difficile 147
 Computed tomography (CT) 116, 118
 Computed tomography pulmonary angiography (CTPA) 118
 Conductance Regulator (CFTR) 117
 Conjunctivitis 9, 150
 Continuous Positive Airway Pressure (CPAP) 117
 COPD (chronic obstructive pulmonary disease) 6, 20, 110, 112, 119, 120, 121, 128, 246
 CPAP (Continuous Positive Airway Pressure) 117
 CRP (C-reactive protein) 250
 Cryptococcal meningitis 157
Cryptococcus neoformans 156
Cryptosporidium oocysts 152
Cyclospora 154
cayetanensis 154
 oocysts 154

D

Defensins 14
 Dendritic cells (DCs) 1, 2, 8, 9, 11, 14, 15, 16, 41, 161, 211, 251, 255, 257, 260
 Directly observed therapy (DOT) 114
 Disability-adjusted life years (DALYs) 121
 Disseminated gonococcal infection (DGI) 189
 DNA 35, 47, 74, 75, 250
 -based formulations 35
 damage 250
 molecules 74
 vaccine delivery 75
 vaccines 47, 74, 75
 Dry powder inhalers (DPIs) 108, 125, 127, 131
 DTaP vaccine 71, 72

E

E. coli 141, 145, 210
 pathogenic 145
 infections 145
 O157 145
 Ebola 66, 73, 75
 EMA (European Medicines Agency) 83, 130, 225
 Engineered genetic circuits 92
 plants 92
 strains 92
Entamoeba histolytica 153
 Epithelial barrier 6, 7, 11, 17, 18, 162, 211, 213
 complex 6
 function 17, 18
 mucosal 11
 specialized 7
 Epitopes 57
Escherichia coli 141, 145, 157

F

Fidaxomicin 148
 Filamentous hemagglutinin 72
 Fluconazole 156, 157
 FMT (fecal microbiota transplantation) 148
 Formulations 1, 3, 8, 21, 25, 92, 93, 106, 125, 126, 127, 129, 209, 224, 229, 262, 263, 265
 adjuvant 92, 94, 263
 chemistry 224
 compatibility 127
 creative 3
 developing novel 265
 developing prodrug 3
 dry powder 106, 125
 higher-dose 263
 improving drug 25
 ingredients 129
 inhalable 127
 injectable 262
 lipid-based 1, 18, 21
 liposomal 125, 126
 liquid 75, 79
 methods 55, 126
 new 127
 optimization 229
 oral 93, 106

Subject Index

permeation-enhancing 3
propellant-based 125
vaccine's 209

G

Gene therapy 1, 21, 22
Genital herpes 191
Genital warts 190, 191
GERD 140
German measles 67
Giardia 141, 151, 152
 cysts 152
 infection 152
 lamblia 151
Glycogen 7
Gonorrhea 173, 174, 176, 179, 183, 186, 189,
 193, 194, 197, 198
Guillain-Barré syndrome 146

H

Hemolytic anemia 145
Hemorrhoids 8
Hepatitis 67, 71, 72, 141, 159, 231
HIV/AIDS 70, 152, 155, 157, 179, 192
 advanced 192
 patients 155
HIV 179, 191, 192
 infection 179, 191
 treatment 192
Homeostasis 6, 8, 16, 161, 249
 intestinal 8
 maintaining 6, 161
 mucosal immune 16
 peripheral T-cell 249
HPV (Human Papillomavirus) 52, 53, 55, 67,
 72, 173, 174, 176, 179, 183, 190, 193,
 194, 197, 198, 206
 antigens 53
 delivering 53
 immunization 183
 -induced cancers 53
 infection 72, 190
 -related diseases 55
 vaccine 72
HSV (herpes simplex virus) 174, 179, 183,
 186, 191, 193, 210
 infection 191
Human Immunodeficiency Virus 191

Mucosal Vaccine Delivery Systems (Part 1) 275

I

IgA (Immunoglobulin A) 13, 19, 36, 37, 43,
 48, 49, 80, 123, 163, 208, 210, 212, 254
 dimeric 48
 monomeric 48
 secretion of 37, 254
 antibodies 13, 19, 49, 123, 163
IgE antibodies 13
IgG antibodies 13
Immunization 130, 221, 222, 265
 safer 265
 sublingual 222
 widespread 221
 acceptance 221
 technique 130
Immunogenicity 1, 56, 57, 68, 72, 75, 81, 82,
 92, 126, 127, 130, 224
Immunoglobulin 9, 13, 43, 80, 208, 213, 254
Immunotherapy 2, 116, 225
Inactivated 71, 86
 polio vaccine (IPV) 71
 Rotavirus Vaccines 86
Induced cross-reactive immunity 259
Infertility 7, 117, 176, 179, 189, 197
Influenza 47, 71, 111, 256, 261, 264
 symptoms 111
 vaccines 71, 261
 virus 47, 256, 264
Innate immunity 11, 12, 211, 248, 251
Irritable bowel syndrome (IBS) 140

L

Lactic 7, 18
 acids 7
 -co-glycolic acid 18
Lactobacilli 7
 -dominated microbiota 7
Lactoferrin 9
Lamina propria 4, 41, 161
Lassa fever 73
Leukotriene modifiers 113
Live attenuated vaccines 39, 46, 69, 70, 71, 92
Liver 153, 159
 abscesses 153
 failure 159
Lymph nodes 80, 212
Lymphatic vessels 161

Lymphocytes 6, 12, 15, 16, 41, 43, 161, 162, 222, 224, 251, 252, 255, 256, 257
 self-reactive 224
 Lymphoid follicles 7, 43, 162, 211
 Lymphoid organs 11, 48, 49, 80
 secondary 48, 49, 80
 structured 11
 Lymphoid tissues 8, 10, 11, 42, 79, 208, 210, 214, 254, 262
 associated 10
 bronchial-associated 208, 210
 gut-associated 214
 mucosal-associated 8, 11, 262
 nasopharynx-associated 254
 nose-associated 42
 underlying 79

M

MALT (Mucosal-associated lymphoid tissue)
 8, 11, 12, 13, 41, 42, 162, 163, 164, 208, 210, 211, 254, 257, 260, 262, 263
 activation 260, 263
 -plasma cells 13
 Measles 67, 73
 vaccine 67
 virus 73
 Memory T-cells 244
 Meningitis 72, 150, 156
 Meningoencephalitis 156
 MERS-CoV 111
 MHC (major histocompatibility complex) 15, 49, 80
 class II molecules 80
 Mucins 5, 214
 Mucociliary clearance mechanism 25
 Mucosae 1, 8, 161
 muscularis 161
 ocular 1
 rectal 8
 Mucosal health 18
 Mumps vaccine 67

N

NALT (Nasal-Associated Lymphoid Tissue)
 35, 41, 42, 43, 254, 260
 acts 43
 follicles 41, 43
 Nasal influenza 50

Neisseria gonorrhoeae 189
Neisseria meningitidis 72

O

OPV (oral polio vaccines) 65, 67, 68, 70, 83, 84, 85
 Oral Cholera Vaccines (OCVs) 87
 Oral rehydration solutions (ORS) 149
 Oral rehydration therapy (ORT) 147
 Oral vaccines 64, 65, 67, 68, 69, 75, 76, 77, 78, 79, 80, 81, 91, 93, 94, 95, 108, 220
 deploying 94
 deployment of 93
 developing 94
 effectiveness of 68
 mechanism of action of 79, 80
 programmable 93
 Oral vaccines bolster 78
 Oral VLP vaccines 92
 OSA (Obstructive Sleep Apnea) 116, 117
 OSA, severe 117
 OSA diagnosis 116

P

PCR (polymerase chain reaction) 114
 PE (Pulmonary Embolism) 118, 119
 Phagocytic activity 49, 248, 252
 increasing 49
 reduced 248, 252
 Phagocytic activity impairment 242
 PID (pelvic inflammatory disease) 176, 179, 189, 197
 Platelet count 145
 Pneumococcal vaccines 262
 Polio vaccine 67, 83
 Poliomyelitis 67, 83
 Polymerase chain reaction (PCR) 114
 Power dynamics 181
 PrEP 193
 Pulmonary mucosa 1, 5, 6

R

Rabies 67
 Recombinant 74, 92
 DNA technology 74, 92
 expression systems 92

Subject Index

Rotavirus 51, 52, 55, 64, 65, 85, 86, 94, 95,
149, 150, 151, 206, 208, 210
RSV (respiratory syncytial virus) 39, 40, 47,
51, 107, 108, 114, 115, 209, 221, 228,
232, 233, 256
Rubella Vaccine 67

S

Salmonella 89, 90, 144
 bacteria 144
 enterica 144
 Typhi 89, 90
SARS-CoV-2 51, 73, 75, 106, 108, 121, 128
Sexually transmitted disease (STD) 143, 146,
147, 189, 191, 192, 206
 Shigella
 boydii 146
 dysenteriae 146
 flexneri 146
 foodborne transmission 147
 genus 146
 sonnei 146
Shigellosis 146, 147
Sinusitis 117
SLNs (solid lipid nanoparticles) 18
Smallpox Vaccine 67
STIs (sexually transmitted infections) 52, 53,
173, 174, 175, 176, 178, 179, 180, 181,
182, 183, 184, 185, 186, 187, 188, 194,
197, 198
 Streptococcus pneumoniae 262
Syphilis 174, 179, 190
 cardiovascular 190
 late-period 190
 primary 190
 secondary 190

T

T-cells 41, 42, 43, 48, 49, 211, 212, 215, 222,
251, 255, 260
T-lymphocytes 8, 12, 248
TCR (T cell receptor) 15, 49, 245
TGFB (Transforming Growth Factor-beta)
251
Toll-like receptors (TLRs) 57
Treponema pallidum 190
Typhoid 65, 89, 90, 91, 94, 95, 227
 fever 65, 89, 90, 94, 95, 227

Mucosal Vaccine Delivery Systems (Part 1) 277

Typhoid vaccines 89, 90, 91

U

Ulcers 190
 Urogenital 173, 174, 175, 176, 177, 178,
179, 181, 183, 185, 186, 187, 192,
193, 194, 195, 196, 197, 198, 207,
210
 pathogens 173, 194, 197
 common 197
 targeted 195
 system 176
 tract 142, 174, 178, 186, 187, 193, 194, 207,
209, 210
 treatment approach 178
 vaccination 173, 174, 175, 176, 177, 178,
179, 181, 183, 185, 186, 187, 193, 197, 198
 vaccines 174, 175, 176, 177, 178, 186, 187,
188, 192, 193, 194, 195, 196, 198
UTIs (urinary tract infections) 173, 174, 178,
207, 210, 242

V

Varicella 69, 70
Venezuelan equine encephalitis virus 73
Vibrio cholerae 51, 52, 147
VLPs (virus-like particles) 72, 92, 164
VSV (vesicular stomatitis virus) 73

Y

Yellow Fever 70

Z

Zika 75
Zostavax vaccine 262



Shaweta Sharma

Dr. Shaweta Sharma, M. Pharm., Ph.D., is currently employed as a Professor at Galgotias University, Greater Noida. She completed her Ph.D. in 2017 from Teerthanker Mahaveer University, Moradabad, U.P., India. She has been contributing to academics for more than 15 years and has published articles in numerous peer-reviewed national and international journals.



Aftab Alam

Dr. Aftab Alam is the Dean-cum-Principal at the School of Pharmacy, Katihar Medical College, Al-Karim University. He previously held key positions at Galgotias University and earned his Ph.D. from Jamia Hamdard. With research experience at the National Institute of Immunology (NII), numerous awards, and international presentations, his expertise spans cancer nanotechnology, drug delivery, and biomedical research. He has published over 50 papers and currently supervises multiple Ph.D. and M.Pharm. students.



Akhil Sharma

Dr. Akhil Sharma, M. Pharm., Ph.D., is currently working as Professor and Principal at R.J. College of Pharmacy, Raipur, Aligarh, U.P., India. He completed his Ph.D. in 2016 from Teerthanker Mahaveer University, Moradabad, U.P., India. He has been serving the pharmacy profession for more than 15 years and has published numerous articles in peer-reviewed national and international journals.